drugset / Trial / NCT01682408

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

NCT01682408

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedOpen-labelBasic science

Summary

Study to Assess the Pharmacokinetics of R406 in Healthy Subjects when Fostamatinib 150 mg is Administered Alone in Fed and Fasted state and in Combination with Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets

Timeline

Start
2012-09
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fostamatinib Small molecule 150 mg
Comparator Ranitidine Unknown 150 mg

Indications

No indication recorded.